Profile: CEL-SCI Corporation is associated with the development of cancer therapy. Multikine® is the first immunotherapeutic agent being developed as a treatment for cancer. This agent harnesses our body's natural ability to fight tumors and acts on multiple targets on the cancer cells. This is the only immunotherapy that directly affects both the tumor cells and activates a robust anti-tumor immune response. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has had surgery or has received radiation or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. L.E.A.P.S.™ is a patented, T-cell modulation, peptide epitope delivery technology that enables us to design and synthesize proprietary peptide immunogens. It consists of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen. The leading product candidate that has been developed from this technology is the CEL-1000 peptide. This peptide has been shown to protect animals against malaria, herpes and cancer.